MSA
GCVRZ

Marino Stram & Associates’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Marino Stram & Associates’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-28
Closed – – 556
2018
Q1 		$0 Hold
28
– – ﹤0.01% 510
2017
Q4 		$0 Buy
+28
New +$11 ﹤0.01% 486

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

Marino Stram & Associates's GCVRZ Position: Q2 2018 in Review

Marino Stram & Associates sold out of Sanofi Contingent Value Rights (GCVRZ) in Q2 2018, closing a stake of 28 shares.

Marino Stram & Associates first reported a position in GCVRZ in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q1 2018. 106 funds tracked by Wall St. Rank hold GCVRZ as of Q2 2018.

  • Marino Stram & Associates reported no remaining Sanofi Contingent Value Rights position as of Q2 2018 after selling out during the quarter.
  • Marino Stram & Associates sold 28 Sanofi Contingent Value Rights shares in Q2 2018.
  • Marino Stram & Associates first reported a position in Sanofi Contingent Value Rights in Q4 2017 and held it in 2 quarters.
  • Marino Stram & Associates's Sanofi Contingent Value Rights position peaked at $0 in Q1 2018.
  • 106 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q2 2018.

Based on Marino Stram & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.